Tarsus Pharmaceuticals, Inc.TARSNASDAQ
Loading
| Metric | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 |
|---|---|---|---|---|---|
| Revenue Growth | +407.86% | +183.68% | +151.54% | +146.68% | +128.39% |
| Gross Profit Growth | +418.40% | +181.68% | +155.03% | +109.70% | +128.91% |
| EBITDA Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Net Income Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| EPS Diluted Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Weighted Average Shares Growth | +20.71% | +11.46% | +12.00% | +11.01% | +10.95% |
| Weighted Average Shares Diluted Growth | +20.71% | +11.46% | +12.00% | +11.01% | +10.95% |
| Dividends per Share Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Operating Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Free Cash Flow Growth | +0.00% | +0.00% | +0.00% | +0.00% | +0.00% |
| Receivables Growth | +171.31% | +104.56% | +95.32% | +145.30% | +81.25% |
| Inventory Growth | -15.67% | -32.98% | +76.45% | +34.79% | +66.87% |
| Asset Growth | +42.00% | +43.37% | +31.35% | +42.06% | +49.12% |
| Book Value per Share Growth | -5.57% | +11.64% | +17.74% | +27.10% | +37.85% |
| Debt Growth | +139.78% | +137.13% | +0.36% | +14.06% | +29.24% |
| R&D Expense Growth | +26.82% | +19.42% | +26.58% | +34.27% | +6.89% |
| SG&A Expenses Growth | +60.52% | +64.79% | +75.22% | +87.59% | +89.31% |